On May 14, 2026, the U.S. Food and Drug Administration (FDA) officially updated the B2B Digital Compliance Statement Guidance, requiring Chinese exporters of medical devices and health technology products targeting the U.S. and Canadian markets to embed a CE/FDA dual-mark compliance statement module with timestamps, digital signatures, and third-party verification links on their official website homepage and specific product pages. This requirement directly affects the efficiency of overseas buyers in conducting online verification of supplier qualifications. Non-compliant official websites may be excluded from the e-procurement whitelists of government agencies, hospitals, and mainstream distributors, and relevant companies should pay close attention.

Event Overview

On May 14, 2026, the U.S. FDA released a new version of the B2B Digital Compliance Statement Guidance. The guidance clarifies that all Chinese suppliers exporting medical devices and health technology products to the U.S. and Canadian markets must deploy verifiable compliance statement modules on their corporate website homepage and each product detail page; these modules must simultaneously support real-time online verification of CE certification numbers and FDA registration numbers, and integrate timestamps, digital signatures, and clickable third-party verification links. All current information is sourced from public documents on the FDA official website, and no other supporting implementation details have been released simultaneously.

Which Market Segments Will Be Affected

Direct Trading Enterprises

For Chinese exporters directly conducting B2B sales to U.S. and Canadian customers, their official websites are the primary entry point for buyers to verify qualifications. If the required dual-mark verification module is not embedded, the procurement process may be obstructed, and electronic inquiries, RFQ responses, and contract signing stages may be automatically blocked by the system or manually downgraded for evaluation.

Manufacturing Enterprises (Including ODM/OEM)

Although they may not sign contracts directly with overseas customers, more and more international brands are incorporating supplier website compliance into their supplier admission review items. Especially when the end customer is a U.S. hospital system or a federal procurement project, if a manufacturer’s official website cannot provide verifiable FDA/CE status, it may lose eligibility for joint bidding or secondary supplier qualification.

Channel Distribution Enterprises (Importers, Distributors, E-commerce Platforms)

As key nodes for transmitting compliance information between China and the U.S., such companies are often required by buyers to provide real-time compliance proof for upstream factories. If the official websites of the Chinese suppliers they represent do not meet the new guidance requirements, their own ability to endorse qualifications will be weakened, affecting platform onboarding, catalog listing, and responsiveness in government procurement.

Supply Chain Service Enterprises (Compliance Consulting, Digital Certification, SaaS Service Providers)

The guidance sets clear requirements for technical implementation (timestamps, digital signatures, third-party verification links), driving increased demand for technical adaptation of compliance statement modules. Service providers need to confirm whether their own solutions support FDA-recognized verification pathways (such as direct connection to the FDA OASIS database, EU NANDO interfaces, etc.), otherwise it will be difficult to meet customers’ implementation needs.

What Key Points Should Relevant Companies or Practitioners Focus On, and How Should They Respond at Present

Pay Attention to the FDA’s Subsequent Implementation Details and Verification Interface Specifications

The current guidance only sets out functional requirements and has not yet specified the exact databases to which third-party verification links should connect (such as the FDA’s FURLS system, the EU’s EUDAMED or NANDO), digital signature algorithm standards (such as the RFC 3161 timestamp protocol), or qualification requirements for timestamp issuing authorities. Companies need to continue tracking supplementary notices on the FDA official website and in the Federal Register.

Prioritize Reviewing Core Products for the U.S. and Canadian Markets and Their Corresponding Website Pages

Not all product lines are subject to this guidance—only medical devices defined under FDA 21 CFR Part 807 and health technology products regulated under the EU MDR are included. Companies should combine this with their own export product list to identify the scope of official website pages that need modification (such as the homepage, product category pages, and individual SKU detail pages), so as to avoid redundant site-wide development.

Differentiate Between Policy Signals and the Actual Pace of Business Implementation

Based on the analysis, this guidance is a mandatory administrative guidance document without a unified transition period, but enforcement at the implementation level depends on adoption by buyers at their own discretion. Observations suggest that large medical groups (such as HCA Healthcare, Vizient) and federal procurement platforms (GSA Advantage!) have already started internal testing of verification logic; meanwhile, small and medium-sized distributors may gradually begin enabling it in Q4 2026. Companies should adopt a strategy of “adapting first for high-priority customers” rather than waiting for the whole industry to move in sync.

Prepare Structured Data Sources for CE and FDA Registration Information in Advance

Embedding the module requires calling dynamic data, including valid registration numbers, certification status, issuance dates, and expiration dates. Companies should verify whether existing CE certificates (issued by EU notified bodies) and FDA listing/approval numbers (obtained through FURLS) are active, and organize them into machine-readable formats (such as JSON-LD) for real-time invocation and display by front-end modules.

Editor’s Viewpoint / Industry Observation

Observably, this guidance does not create new compliance obligations, but rather shifts existing CE/FDA qualification requirements from “document delivery” to “digital verifiability,” essentially improving the level of automated trust across the B2B transaction chain. Analysis shows, it currently resembles more of a structural signal: it marks that regulators are pushing global supply chain qualification management from “static filing” toward “dynamic verifiability.” The industry needs to continue watching two points: first, whether verification links will form a de facto mutual-recognition interface standard; second, whether non-medical-device health products (such as AI-assisted diagnostic software and remote monitoring SaaS) will subsequently be included in expanded coverage. This is not only a matter of technical adaptation, but also an important point for Chinese companies to align their digital infrastructure with the international regulatory context.

Conclusion: this guidance does not raise the entry thresholds for CE or FDA approval itself, but it significantly raises the threshold for the online credibility of qualification information. At present, it is more appropriately understood as a launch signal for “digital compliance capability building”—it does not replace existing certification processes, but enables certification results to become truly “visible, verifiable, and trustworthy” in B2B scenarios. For companies, the response priority is not to quickly put modules online, but to clarify the matching relationship among their own qualification status, verification pathways, and customers’ actual trust-adoption mechanisms.

Explanation of information sources:
Main source: the B2B Digital Compliance Statement Guidance published on the official FDA website (effective version dated May 14, 2026).
Items pending continued observation: the FDA has not yet published the technical white paper for verification link integration, the list of accredited third-party institutions, or the buyer implementation timetable, and the relevant content requires continued follow-up and updates.